Age-related Macular Degeneration (AMD) Integrative Biology Initiative: Discovery of AMD Pathobiology using Patient-Derived Induced Pluripotent Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE) (U01 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) aims to support collaborative studies of a unique resource of patient-derived induced pluripotent stem cell (iPSC) lines generated by the NEI age-related macular degeneration (AMD) Integrative Biology Initiative. This resource also includes clinical, genomic, and imaging data from the patients from which these cells were derived, and a set of isogenic control cell lines in which the risk allele(s) have been corrected. These cell lines and clinical data are from patients with AMD carrying high prevalence risk alleles selected from the Age-Related Eye Disease Study 2 (AREDS2). The goal of this FOA is to determine if these iPSC-derived cell lines can be used to discover the underlying pathophysiology of AMD. Collaborative effort is highly encouraged with investigators bringing in the needed areas of expertise for successful projects.


  • Letter of Intent Due Date(s): January 22, 2022

  • Application Due Date: Feb. 17, 2022

RFA-EY-21-002 Expiration Date February 18, 2022

Agency Website

Eligibility Requirements

This FOA strongly encourages the establishment of multidisciplinary research teams to study late-onset neurodegenerative diseases and may include investigators from the outside of eye research community with the complementary expertise required to address the goals of this FOA. The teams funded will convene at regular intervals and collaborate as an NEI-led consortium. Grantees under this FOA are expected to share data and technology with other members of the consortium. PD(s)/PI(s) funded through this RFA are required to attend annual in-person/virtual investigator meetings and quarterly videoconferences to share information and ideas, foster collaborations, and accelerate progress toward the AMD Integrative Biology Initiative. Travel expenses to attend these meetings should be included in the budget. Sharing data and technology among the members of the consortium is expected at the earliest stages of the research and with the broader scientific community after the completion of the project.



Amount Description

Budgets are limited to $250,000 in Direct Costs per year. .

The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Funding Type





Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science

External Deadline

February 17, 2022